Lilly rides Mounjaro, Zepbound to better
Time:2024-05-21 19:30:15 Source:politicsViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:Target to lower prices on basic goods in response to inflation
Next:Hall of Fame outfielder Ken Griffey Jr. to lead Indianapolis 500 field in Corvette pace car
You may also like
- Hollywood star Shia LaBeouf is spotted on the streets of Gavin and Stacey's hometown Barry
- Advanced technologies spur low
- Chinese police take back 130 gambling, scam suspects from Cambodia
- In pics: Wudongde hydropower station in SW China
- Not so Cool Britannia! Noel Gallagher gives damning verdict on Keir Starmer
- Chinese scientists precisely monitor solar radiation on Earth's surface
- Excessive nitrogen fertilizer yields less attractive apples: research
- Chinese, Brazilian scientists name new flying reptiles to mark collaboration
- Minnesota Uber and Lyft driver pay package beats deadline to win approval in Legislature